Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT05296941
Recruiting Not applicable

Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD)

NCT05296941 · tracked via the Priya Life Science Sweden tracker
Sponsor
Dalarna County Council, Sweden
Phase
Not applicable
Started
2023-08-01
Last updated
2023-09-08

Condition(s) studied

Mouth Neoplasms

Investigational drug(s) / intervention(s)

Brush sampling

Brush sampling: Brush sampling instead of surgical biopsy for control of reaccurance

Study summary

Cancer is a complex disease; its different causes and types have a strong impact on patient treatment and prognosis. To improve understanding of the disease, its causes and progression, the investigators will develop a simple, cost-effective system for continuous control of mucosal lesions with non-invasive brush biopsy that can be managed in primary dental care, as an alternative to tissue biopsy in order to reduce the number of oral cavity cancers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: • Persons 18 years of age or older who have the clinical diagnosis of leukoplakia, erythroplakia or proliferative verrukös leukoplakia Exclusion Criteria: * People who cannot read and understand information in Swedish. * Ongoing chemotherapy and/or radiotherapy.

Primary outcome measure(s)

  • Numbers of cancers diagnosed by brush sampling — 5 years

Trial sites (1)

FacilityCityRegionStatus
Kristina Edman Falun Dalarna County Recruiting

More Dalarna County Council, Sweden trials in Sweden

Bowel And Bladder Function in Infant Toilet Training Active, not recruiting
Effects of Negative Pressure Wound Bandaging After Mastectomy Recruiting
Stability of Hand Grip Strength Across a Competitive Season in Elite Male and Female Ice Hockey Players Starting soon
PEP-device for Treatment of Swimming-induced Pulmonary Edema (SIPE) Recruiting
O2 Versus CPAP Treatment Of Patients Undergoing SIPE Therapy (OCTOPUS) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05296941 on ClinicalTrials.gov ↗ ← All trials in Sweden